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Objective. The aim of this overview was to evaluate and summarize Cochrane reviews of traditional Chinese herbal products
(TCHPs) as the treatment for coronary heart disease (CHD). Methods. We searched the Cochrane Database that was concerned
with the eﬀectiveness of TCHPs for CHD. We also searched the Cochrane Central Register of Controlled Trials. Reviews and
primarystudiesofTCHPasthetreatmentofanytypeofCHDwereincluded.Datawereextractedaccordingtopredeﬁnedinclusion
criteria by two independent reviewers. Results. Six Cochrane reviews were included. They related to a wide range of TCHPs for
diﬀerent types of CHD. Four reviews were concerned with angina pectoris (unstable or stable), one review was concerned with
heart failure, and for acute myocardial infarction. No reviews concluded that TCHPs were deﬁnitely eﬀective for CHD because of
the weak evidence. Eight primary studies were TCHPs from CHD. These studies also maybe result in bias, but better than before.
Conclusion. Several Cochrane reviews of TCHPs for the treatment of diﬀerent types of CHD have recently been published. None
of these reviews got deﬁnite conclusion favoring the eﬀectiveness of TCHPs due to the weak evidence. With the improved quality
of the new registered RCTs. The potential role of TCHPs in treating CHD is anticipated to be detected.
1.Introduction
Coronary heart disease (CHD) is one of the most dangerous
threats to human health, manifested by diﬀerent clinical
types such as angina pectoris, myocardial infarction, heart
failure, cardiac arrhythmia, and so forth. Although treated
with intensive medication or revascularization therapy,
uncontrolled angina and recurrent acute cardiovascular
events are still the major problems confronting modern
medicine. Traditional Chinese medicine (TCM) has a history
of thousands of years and has made great contributions
to the health and well-being of the people and to the
maintenance and growth of the population [1]. Currently,
more than 90% of the urban and rural Chinese population
has sought for TCM in their lifetimes [2]. TCM has been
studied extensively and seems to be safe and eﬀective in
treating CHD [3, 4]. Recently, the potential beneﬁt of
integrative Western and Chinese medicine regimen has also
been indicated in a large-scale registry study in China [5].
Cochrane reviews are regarded as the highest standard of
evidence [6]. They adopt transparent and comprehensive
methods of ﬁnding all of the relevant evidence. Their quality
and reliability are generally higher than any other systematic
review because they employ a predeﬁned, rigorous, and
explicit methodology. Cochrane reviews are also reviewed
and published in advance. Therefore, conclusion made from
the overview of Cochrane reviews is more credible. Some
Cochrane systematic reviews of traditional Chinese herbal
products (TCHPs) for CHD have been conducted in recent
years. These reviews provide preliminary evidence of TCHPs
beneﬁts to certain CHD patient populations, which call for
a comprehensive evaluation on the eﬀectiveness of TCHPs
in CHD patients. This overview aims to evaluate and
summarize all Cochrane reviews of TCHP as a treatment of
CHD critically.
2. Methods
We searched the titles and abstracts of all reviews in Septem-
ber 2011 of the Cochrane Database of Systematic Review.2 Evidence-Based Complementary and Alternative Medicine
Table 1: Cochrane Reviews of TCHP for CHD.
First author TCHP Control group Condition Number of
RCTs Participants Conclusion
Wu et al. [8] Danshen as part of
decoction Diﬀerent basic treatment Acute myocardial infarction 6 2368 B
Wang et al. [9] Puerarin Diﬀerent basic treatment Unstable angina pectoris 20 1240 A
Zheng et al. [10] Diﬀerent forms of
Shengmai Diﬀerent basic treatment Heart failure 6 440 A
Duan et al. [11] Suxiao jiuxin wan Isosorbide dinitrate or
nitroglycerin or other TCHP Angina pectoris 15 1776 A
Wu et al. [12] Tongxinluo Diﬀerent basic treatment Unstable angina pectoris 18 1413 A
Zhuo et al. [13] Diﬀerent herbal
products
Isosorbide dinitrate or other
TCHP Stable angina 3 216 B
Notes: RCT: randomized clinical trial.
A: TCHP may be or appears to be eﬀective.
B: The evidence is insuﬃcient, reliable conclusions could not be drawn.
The search terms were “Herb∗ and medic∗ and heart” and
“Herb∗ and medic∗ and cardiac” and “Herb∗ and medic∗
and circulation” and “Chinese and heart” and “Chinese and
cardiac” and “Chinese and circulation.” We read the title and
abstract of each retrieved review in order to conﬁrm that the
review was relevant. Articles were included if they related
t oa n yt y p eo fT C H Pa sat r e a t m e n to fC H D .D a t aw e r e
extracted according to predeﬁned inclusion criteria by two
independent reviewers (Qiu Y. and Xu H.). Disagreements
were resolved by discussion between the authors.
We also searched the Cochrane Central Register of
ControlledTrials(CENTRAL)inTheCochraneLibraryIssue
4 of 4, Oct 2011. Studies of TCHP as the treatment of
any type of CHD were included. Studies without results
were excluded. The methodological quality was assessed
using the Cochrane Collaboration risk of bias criteria with
6 domains [7]: (1) random, (2) blinding of participants,
doctor, and outcome assessors, (3) allocation concealment,
(4) incomplete outcome data, (5) free of the suggestion
of selective outcome reporting, and (6) informed consents.
Discrepancieswereresolvedbyconsensusthroughdiscussion
between the two reviewers.
3. Results
Six articles met our inclusion criteria (Table 1)[ 8–13]. The
Cochranereviewsincludedwerepublishedbetween2006and
2011. The studies in these reviews mainly originated from
China. They included between 3 and 18 primary studies.
Four reviews were concerned with angina pectoris (unstable
or stable) [9, 11–13], one review was concerned with heart
failure [10] (heart failure was primary caused by CHD), and
one review was concerned with acute myocardial infarction
[8].
Four Cochrane reviews concluded positively that TCHP
may be or appears to be eﬀective. Two reviews showed that
the evidence is too weak to make conclusion. No reviews
made deﬁnite conclusion. All reviews indicated that high-
quality trials are required to assess the eﬃcacy and safety
of TCHP for CHD and the ﬁnding should be interpreted
with care because of the very low methodological quality of
studies and potential publication bias.
There are 69 studies in the six reviews. Two studies were
reported from 1981 to 1985; one study was reported from
1986 to 1990; three studies were reported from 1991 to
1995; twenty-six studies were reported from 1996 to 2000;
thirty-ﬁve studies were reported from 2001 to 2005; only two
studieswerereportedfrom2006to2011.Therefore,themost
likely reason for the weak evidence of TCHP for CHD is the
previous poor methodology.
The randomized clinical trials (RCTs) contained in four
Cochrane reviews [8–10, 12] were mainly on the basis of
conventional western medicine. But the basic treatment is
not unchangeable. The RCTslisted in two Cochrane reviews
[11,13]directlycontrastedoneTCHPwithwesternmedicine
or other TCHP. Two Cochrane reviews [8, 13] summarized
diﬀerent TCHP for CHD. The TCHP mentioned in these
RCTs were injection (e.g., Shengmai Injection, Puerarin),
oral Chinese patent medicine (e.g., Yi Xin Mai, Bao Xin
Bao, Li Nao Xin, Shengmai Oral Liquid, Suxiao Jiuxin Wan,
Tong Xin Luo), or Chinese herbal decoction. Four Cochrane
reviews [9–12] summarized single TCHP for CHD.
In order to assess the status of the quality of the studies
of TCHP, we also searched the CENTRAL in The Cochrane
Library Issue 4 of 4 Oct 2011. Eight studies were included
(Table 2)[ 14–21]. These studies primary originated from
China. These studies were all making an explicit statement
that the participants were randomly assigned to diﬀerent
groups, but two were not describing the details. Only four
RCTS adopted the application of blinding: one did not
report details [18] and three reported that the participants
and doctors were blind [14, 19, 21]. One of the trials
adopted allocation concealment [14]. Trials with inadequate
blinding and inadequate allocation concealment may result
in limited evidence. Six trials did well in the incomplete
outcome data adequately addressed [14–16, 18, 19, 21].
Only one trial did well in the free of the suggestion of
selective outcome reporting [18]. Not every trial made
explicit statement that the participants signed the informed
consents [16, 17, 19]. These RCTs had more participantsEvidence-Based Complementary and Alternative Medicine 3
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than usual RCTs. They usually have 60 to 100 participants
[15–18, 20, 21]; only 1 RCT has 35 participants [19]a n d1
RCThas859participants[14].Theseshortcomingshighlight
the importance of following CONSORT procedures in the
future studies [22]. Anyway, the quality of primary studies
was better than before, and we still need further progress.
4. Discussion
The current Cochrane reviews indicated the potential beneﬁt
of TCHP in treating CHD, but none of them drew a
deﬁnite conclusion because of the poor quality of primary
studies. Although Cochrane reviews have the reputation for
being more transparent and rigorous than other systematic
reviews, the conclusion needs further discussion. The RCTs
listed in two reviews [8, 13] were not the same TCHP. The
treatments in the control groups, and the durations of the
RCTs were also varied. In addition, diﬀerent TCHP applys
to diﬀerent syndrome according to TCM theory. All of these
reviews did not involve this question.
Therefore, four reviews [9–12] about single TCHP are
more persuasive. They all made the conclusion of “A,”
indicating the TCHP may be or appears to be eﬀective. The
other two reviews made the conclusion of “B.” One review
about “Danshen for acute myocardial infarction” concerned
with the herb Danshen, but Danshen was not the only part
of the treatment. Thus the heterogeneity of included RCTs
cannot be ignored. The other review of “herbal products
for stable angina” is concerned with three diﬀerent TCHPs
comparing with isosorbide dinitrate [13]. It also made the
conclusion of “B,” indicating the evidence is insuﬃcient and
reliable conclusions could not be drawn.
In conclusion, although some Cochrane reviews have
shown the potential beneﬁt of TCHP in treating CHD, more
evidence from high-quality trials is needed to support the
clinical use of TCHP. However, well-designed randomized
clinical trials of TCHP with rigorous methodology are in
progress or have been completed at several institutions
around the world [6]. We hope that the eﬀectiveness and
safety of TCHP can be conﬁrmed in the near future.
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